Martin Schrappe

Country flagGermany

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (14)

Year:

2026

Year:

2026

Year:

2026

Year:

2025

PURPOSE Modern ALL therapy aims to reduce toxicity, while maintaining and improving the current high cure rates. Acute and late sequelae of anthracyclines are of major concern. The AIEOP-BFM ALL 2009 trial aimed to clarify the need for anthracyclines in low-risk patients. PATIENTS AND METHODS After 2 weeks of induction therapy, which included two daunorubicin (DNR) doses once weekly (30 mg/m 2 each) as part of a 4-drug therapy, patients age 1-17 years with newly diagnosed non–high-risk B-ALL either positive for ETV6::RUNX1 or with rapid treatment response, as assessed by induction day-15 evaluation, were randomly assigned to receive either two additional doses of DNR (control arm [CA]) or no further DNR during induction (experimental arm [EA]). Patients treated as randomly assigned were included in the primary analysis on noninferiority in event-free survival (EFS). Adverse reactions of special interest (ARSI) were analyzed in the as-treated population. RESULTS Of 6,136 patients enrolled in AIEOP-BFM ALL 2009, 2,514 patients (41.0%) were eligible for this random assignment, with 82.7% actually randomly assigned (EA: n = 1,040 and CA: n = 1,039). The 5-year EFS was 92.5% (SE 0.8%) in CA and 92.2% (SE 0.9%) in EA. Accordingly, cumulative incidence of relapse was 5.8% (SE 0.7%) and 5.7% (SE 0.7%), and overall survival was 97.6% (SE 0.5%) and 97.4% (SE 0.5%) in CA and EA, respectively. Life-threatening and fatal ARSI were similar in the two arms, but there was a three times lower incidence of invasive fungal infections in the EA (0.5% v 1.5%, P = .02). CONCLUSION A reduced DNR dose during induction did not compromise the outcome of patients with favorable prognostic factors but did diminish infectious toxicity indicated by the lower rate of invasive fungal infections.

Year:

2025

A–C, Multivariate Cox proportional hazard model for EFS. The variables “vitamin D deficiency” (defined by a 25 OH vitamin D level 47 pg/mL), sex and age at diagnosis were investigated for EFS in the groups: embryonal malignancies ( A ) lymphatic malignancies ( B ) and malignant primary brain tumor (PBT; C ).

Year:

2024

A and B, EFS in the entire group and in six diagnostic groups. HR and 95% confidence interval (CI) for the presence of a vitamin D deficiency (25 OH vitamin D level at or below 30 nmol/L) at any time during the 5 years following the initial diagnosis is shown in A , and for the presence of PTH levels at or above 47 pg/mL (= median of the group) is shown in B . A univariate analysis was performed.

Year:

2024

A–C, EFS in subgroups with PTH as a continuous variable. Visualizing of the highest measured PTH on time-to-event (as EFS) in a model assuming a linear PTH-effect in the subgroups of embryonal malignancies ( A ) lymphatic malignancies ( B ) and malignant primary brain tumor (PBT; C ). For the analyses, the highest PTH at diagnosis or during the following 5-year period was used.

Year:

2024

Clinical characteristics of the group of patients with PTH levels below the group-median (47 pg/mL; PTH− group, first column), the patients with PTH levels ≥ the median (PTH+ group, middle column), and the entire group (last column).

Year:

2024

A–C, Kaplan–Meier plots showing EFS in subgroups. The Kaplan–Meier plots show the EFS in the groups of embryonal malignancies ( A ) lymphatic malignancies ( B ) and malignant primary brain tumor (PBT; C ) for patients with PTH at/above the median (47 pg/mL) of the entire group (orange line) and patients with PTH levels below the median (gray line). For the analyses, the highest PTH at diagnosis or during the following 5-year period was used. P values from paired log rank tests are provided.

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Collaborators (35)

Shondra Pruett-Miller

Associate Member

St. Jude Children's Research Hospital

UNITED STATES
View details

Mariko Eguchi

Profesor

Ehime University Graduate School of Medicine

JAPAN
View details

Chi Kong Li

Professor

The Chinese University of Hong Kong (CUHK)

HONG KONG
View details

riccardo masetti

Assistant Professor

University of Bologna

ITALY
View details

Kjeld Schmiegelow

-

DENMARK
View details

Hanne Vibeke Hansen Marquart

Chief Physician; MD, PhD, Clinical Associate Professor

Copenhagen University Hospital

DENMARK
View details

Allen Eng Juh Yeoh

National University of Singapore (NUS)

SINGAPORE
View details

Corinna Grasemann

Head of Pediatrics

University Medical Center of the Johannes Gutenberg University Mainz

GERMANY
View details

Atsushi Manabe

Professor

Hokkaido University

JAPAN
View details

Wolfgang Hoegler

Professor of Paediatrics

-

AUSTRIA
View details

Gabriele Escherich

-

GERMANY
View details

Valentino Conter

-

ITALY
View details

John Choi

The University of Alabama

UNITED STATES
View details

Franco Locatelli

Full Professor of Pediatrics

Catholic University of the Sacred Heart

ITALY
View details

Steven Kornblau

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Junko Takita

教授 / Professor

Kyoto University

JAPAN
View details

Szymon Skoczen

Associated Professor

Uniwersytet Jagiellonski Collegium Medicum

POLAND
View details

Kathryn Roberts

St. Jude Children's Research Hospital

UNITED STATES
View details

David Teachey

Professor

Children's Hospital of Philadelphia

UNITED STATES
View details

Cristina Matteo

Istituto di Ricerche Farmacologiche Mario Negri IRCCS

ITALY
View details

Daisuke Tomizawa

Head

National Center For Child Health and Development

JAPAN
View details

Cheng Cheng

Professor

St Jude Grade School of Biomedical Sciences

UNITED STATES
View details

Motohiro Kato

-

JAPAN
View details

Takao Deguchi

Head of Division

National Center For Child Health and Development

JAPAN
View details

Ching-Hon Pui

Fahad Nasser Al-Rashid Chair of Leukemia Research

St. Jude Children's Research Hospital

UNITED STATES
View details

Andrew Moore

Associate Professor

University of Queensland

AUSTRALIA
View details

Ilaria Iacobucci

Principal Scientist

St. Jude Children's Research Hospital

UNITED STATES
View details

Masatoshi Takagi

Tokyo Medical and Dental University

JAPAN
View details

Zhaohui Gu

Assistant Professor

Beckman Research Institute, City of Hope

UNITED STATES
View details

Paul G Thomas

Professor

Fred Hutch Cancer Center

UNITED STATES
View details

Andishe Attarbaschi

Medical University of Vienna

AUSTRIA
View details

Carmelo Rizzari

Professor

University of Milano-Bicocca

ITALY
View details

Charles Mullighan

Senior Deputy Director, St. Jude Children's Research Hospital Comprehensive Cancer Center

St. Jude Children's Research Hospital

UNITED STATES
View details

Rishi Kotecha

Professor

Telethon Kids Institute

AUSTRALIA
View details

Klaus-Michael Debatin

Professor of Pediatrics

Universität Ulm

GERMANY
View details